drugset / Trial / NCT00544921
Phase 1 Study of Anti-glycation Agent GLY-230 in Healthy Subjects
RandomizedParallel-groupOpen-label
Summary
To test the safety of GLY-230 and to evaluate how long drug stays in blood after taking it by mouth.
Timeline
- Start
- 2005-10
- Primary completion
- 2006-10
- Completion
- 2006-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GLY-230 | Other / unclassified | 50 mg | Oral |
| Subject | GLY-230 | Other / unclassified | 100 mg | Oral |
| Subject | GLY-230 | Other / unclassified | 250 mg | Oral |
| Subject | GLY-230 | Other / unclassified | 500 mg | Oral |
| Subject | GLY-230 | Other / unclassified | 750 mg | Oral |
| Subject | GLY-230 | Other / unclassified | 1000 mg | Oral |